$116.16
-0.95
(-0.81%)
As of Oct 22, 2026, 9:31 PM EDT · cached
Price history
Haemonetics Corp (HAE) is trading down at $116.16 (-0.81%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Haemonetics Corp revenue & net income history (FY2017–FY2026)
RevenueNet incomeNet margin (right axis, %)
| FY2017Apr 2017 | FY2018Mar 2018 | FY2019Mar 2019 | FY2020Mar 2020 | FY2021Apr 2021 | FY2022Apr 2022 | FY2023Apr 2023 | FY2024Mar 2024 | FY2025Mar 2025 | FY2026Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $886.1M | $903.9M | $967.6M | $988.5M | $870.5M | $993.2M | $1.17B | $1.31B | $1.36B | $1.33B |
| Growth (year over year) | −2.5% | +2.0% | +7.0% | +2.2% | −11.9% | +14.1% | +17.7% | +12.0% | +4.0% | −2.0% |
| Gross profit | $378.5M | $411.9M | $417.5M | $484.5M | $397.8M | $505.5M | $615.1M | $691.5M | $749.0M | $787.6M |
| Gross margin | 42.7% | 45.6% | 43.2% | 49.0% | 45.7% | 50.9% | 52.6% | 52.8% | 55.0% | 59.0% |
| Operating income | −$19.4M | $56.2M | $83.5M | $103.4M | $89.7M | $80.8M | $156.0M | $164.9M | $221.8M | $156.7M |
| Operating margin | −2.2% | 6.2% | 8.6% | 10.5% | 10.3% | 8.1% | 13.4% | 12.6% | 16.3% | 11.7% |
| Net income | −$26.3M | $45.6M | $55.0M | $76.5M | $79.5M | $43.4M | $115.4M | $117.6M | $167.7M | $97.3M |
| Net margin | −3.0% | 5.0% | 5.7% | 7.7% | 9.1% | 4.4% | 9.9% | 9.0% | 12.3% | 7.3% |
| EPS (diluted) | −$0.51 | $0.85 | $1.04 | $1.48 | $1.55 | $0.84 | $2.24 | $2.29 | $3.31 | $2.05 |
| Balance sheet | ||||||||||
| Cash and equivalents | $139.6M | $180.2M | $169.4M | $137.3M | $192.3M | $259.5M | $284.5M | $178.8M | $306.8M | $245.4M |
| Total assets | $1.24B | $1.24B | $1.27B | $1.27B | $1.82B | $1.86B | $1.93B | $2.20B | $2.45B | $2.40B |
| Total liabilities | $499.1M | $484.9M | $606.9M | $680.0M | $1.09B | $1.11B | $1.12B | $1.24B | $1.63B | $1.60B |
| Long-term debt | $253.6M | $59.4M | $322.5M | $305.5M | $690.6M | $559.4M | $754.1M | $797.6M | $921.2M | $1.22B |
| Shareholders' equity | $739.6M | $752.4M | $667.9M | $587.1M | $731.7M | $749.4M | $818.0M | $960.0M | $820.8M | $796.3M |
| Cash flow | ||||||||||
| Operating cash flow | $159.7M | $220.3M | $159.3M | $158.2M | $108.8M | $172.3M | $273.1M | $181.8M | $181.7M | $293.2M |
| Capital expenditure | $76.1M | $74.8M | $119.0M | $48.8M | $37.0M | $96.5M | $191.3M | $38.1M | $39.3M | $32.8M |
| Free cash flow | $83.6M | $145.6M | $40.3M | $109.5M | $71.8M | $75.8M | $81.7M | $143.6M | $142.4M | $260.4M |
| Share buybacks | $0 | $100.0M | $160.0M | $175.0M | $0 | $0 | $75.0M | $0 | $225.0M | $175.0M |
RevenueNet incomeNet margin (right axis, %)
| Q2 FY25Sep 2024 | Q3 FY25Dec 2024 | Q4 FY25†Mar 2025 | Q1 FY26Jun 2025 | Q2 FY26Sep 2025 | Q3 FY26Dec 2025 | Q4 FY26†Mar 2026 | Q1 FY27Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $345.5M | $348.5M | $330.6M | $321.4M | $327.3M | $339.0M | $346.4M | $339.4M |
| Growth (year over year) | +8.6% | +3.7% | −3.7% | −4.4% | −5.3% | −2.7% | +4.8% | +5.6% |
| Gross profit | $187.4M | $193.5M | $193.1M | $192.2M | $194.7M | $202.4M | $198.2M | $202.8M |
| Gross margin | 54.2% | 55.5% | 58.4% | 59.8% | 59.5% | 59.7% | 57.2% | 59.8% |
| Operating income | $51.7M | $59.0M | $71.3M | $53.9M | $58.5M | $67.4M | −$23.0M | $57.5M |
| Operating margin | 15.0% | 16.9% | 21.6% | 16.8% | 17.9% | 19.9% | −6.6% | 16.9% |
| Net income | $33.8M | $37.5M | $58.0M | $34.0M | $38.7M | $44.7M | −$20.1M | $33.0M |
| Net margin | 9.8% | 10.8% | 17.5% | 10.6% | 11.8% | 13.2% | −5.8% | 9.7% |
| EPS (diluted) | $0.66 | $0.74 | $1.17 | $0.70 | $0.81 | $0.95 | −$0.41 | $0.72 |
| Balance sheet | ||||||||
| Cash and equivalents | $299.3M | $320.8M | $306.8M | $292.9M | $296.4M | $363.4M | $245.4M | $223.4M |
| Total assets | $2.53B | $2.53B | $2.45B | $2.46B | $2.44B | $2.49B | $2.40B | $2.37B |
| Total liabilities | $1.65B | $1.62B | $1.63B | $1.58B | $1.59B | $1.58B | $1.60B | $1.53B |
| Long-term debt | $1.22B | $1.22B | $921.2M | $920.8M | $920.4M | $920.0M | $1.22B | $1.17B |
| Shareholders' equity | $878.9M | $906.9M | $820.8M | $882.3M | $849.2M | $911.5M | $796.3M | $837.1M |
| Cash flow | ||||||||
| Operating cash flow | $48.8M | $43.8M | $116.6M | $17.4M | $111.3M | $93.6M | $70.9M | $52.3M |
| Capital expenditure | $9.43M | $8.55M | $15.6M | $3.75M | $5.02M | $6.35M | $17.7M | $7.91M |
| Free cash flow | $39.4M | $35.2M | $100.9M | $13.6M | $106.3M | $87.2M | $53.3M | $44.4M |
| Share buybacks | — | $0 | $150.0M | — | — | $0 | $100.0M | — |
From Haemonetics Corp's 10-K and 10-Q filings with the SEC; its fiscal year ends in March. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Haemonetics Corp
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Source: Wikipedia — Haemonetics
- Headquarters
- Boston, Massachusetts From SEC filings, Oct 2026
Recent News (5)
-
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE —Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients’ individual needs and preferences—
-
Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System BOSTON, Oct. 19, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today an…
-
-
Stocks making the biggest moves premarket: Haemonetics, Broadcom, Lululemon, Palantir, Wolfspeed & more Stocks making the biggest moves premarket: Haemonetics, Broadcom, Lululemon, Palantir, Wolfspeed & more CNBC
-
Pharvaris at Wells Fargo conference: oral HAE drug gains ground
Pharvaris at Wells Fargo conference: oral HAE drug gains ground
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International